Self-Cut Mesh Noninferior for Pelvic Organ Prolapse Procedure

WEDNESDAY, Sept. 21, 2022 (HealthDay News) -- Using the same titanium-coated polypropylene mesh, the surgical success rate with self-cut mesh is noninferior to that with a commercial mesh kit for the transvaginal treatment of severe pelvic organ prolapse (POP), according to a study published online Sept. 16 in JAMA Network Open.
Juan Chen, M.D., Ph.D., from the Chinese Academy of Medical Science and Peking Union Medical College in Beijing, and colleagues conducted a randomized clinical trial to assess the one-year effectiveness and safety of self-cut titanium-coated polypropylene mesh (169 patients) versus a precut commercial mesh kit (167 patients) for the transvaginal surgical treatment of women with severe symptomatic POP.
The researchers found that 95.9 percent in the self-cut mesh group met the definition of surgical success, which was noninferior to the surgical success rate achieved in the mesh-kit group (87.4 percent). There was no significant difference in the frequency of Clavien-Dindo grade 1 to 3 perioperative complications (7.2 percent in the self-cut mesh group versus 12.4 percent in the mesh-kit group). At one year, vaginal mesh exposure rates were similar (2.4 percent in the self-cut mesh group versus 4.8 percent in the mesh-kit group). Finally, there was a savings of $2,481.00 (40.4 percent) with the use of self-cut mesh when comparing median total hospitalization costs.
"Self-cut mesh procedures may be advantageous for some patients in countries with low and middle income," the authors write.
Related Posts
Air Pollution Adversely Linked to Body Composition in Women
MONDAY, Oct. 31, 2022 (HealthDay News) -- Exposure to air pollution is adversely...
Una respuesta inmune ‘débil’ podría explicar por qué la COVID es más dura para las personas obesas
MIÉRCOLES, 22 de marzo de 2023 (HealthDay News) -- La obesidad es un factor de...
Telemedicine, In-Person Visits Show High Diagnostic Concordance
MONDAY, Sept. 12, 2022 (HealthDay News) -- Telemedicine and in-person diagnoses...
COVID-19 Convalescent Plasma Seems Safe for High-Risk Children
TUESDAY, Feb. 8, 2022 (HealthDay News) -- High-titer COVID-19 convalescent...